Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT in steroid ineligible alcoholic hepatitis
NCT05285592Unknown
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Apr 2022
- Primary completion
- Mar 2024
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Randomised, open-label trial of allogeneic fecal microbiota in alcoholic hepatitis (AH), sponsored by Institute of Liver and Biliary Sciences. Primary endpoint: Mortality at 3 months. Status: unknown.
02
Drugs
allogeneic fecal microbiota
03
Conditions
alcoholic hepatitis (AH)
Beyond the preview
Go deeper on NCT05285592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05285592.